The mRhythm Study, an initiative of Cardiogram, the startup involved in providing a workable roadmap to the heart rate data of Apple Watch, has shown that atrial fibrillations can be detected with 97 percent accuracy through algorithms.
In 2010, around 130 brands like Zoloft and Lipitor constituted for 34% of the universal pharma sector sales. Following the same year, many other drug companies hewed from the permit. The sector has changed in countless ways.
Diabetes Australia's (the third oldest diabetes association in the world) latest figures show that over 200,000 women have suffered gestational diabetes during the last 10 years and is expected to exceed 500,000 within the next decade. Gestational diabetes can be fatal if untreated and could likely lead to overweight babies, premature births, as well as PreEclampsia.
The Internet of Things (IoT) has changed the functionalities of the medical and healthcare sectors and has brought significant changes in the healthcare services delivery model.
Finland pharmaceuticals company Faron (AIM: FARN) has crashed almost 90% of its shares, as the company announced the Phase III INTEREST trial of traumakine failed to meet its efficacy endpoint.
A technology that can change the way women check their baby’s health is in the final stages of development. PulseNmore LTD, an Israeli startup is developing a handheld ultrasound device that can be connected to any smartphone for monitoring the growth of a fetus.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder. The company plans to seek regulatory approval for its ketamine-based esketamine nasal spray this year and if given the green light it will be the first new approach for the indication in nearly 50 years.
It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
The questionnaire raised queries on the basis of key parameters like empathy for healthcare providers, quality content and motivation for patients. However, qualities like credible scientific content and values not related to promotional activities emerged as strong criterion for building trust.
The US-Based MiMedx group's (a manufacturer of regenerative medicine) shares fell 20% after the federal prosecutors charged three healthcare professional for accepting bribes from Mimedx. Of these shares, 7.5% recovered when closing for the day.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.